Market Overview:
The global metabolomics biomarker market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth of the market can be attributed to the increasing demand for precision medicine, rising prevalence of chronic diseases, and technological advancements in metabolomics biomarkers. The protein marker segment is expected to dominate the global metabolomics biomarker market in terms of revenue during the forecast period. This segment is anticipated to grow at a CAGR of 11% from 2018 to 2030. The nucleic acid marker segment is projected to grow at a CAGR of 9% during the forecast period owing to its growing application in toxicological studies, drug testing, and cancer diagnosis.
Product Definition:
Metabolomics biomarkers are metabolites that can be used to measure the activity or health of a cell, tissue, organ or organism. They are important because they can provide information about how a particular cell is functioning and what kind of drugs or treatments might be effective.
Protein Marker:
Protein Marker is a chemical that is added to the test sample in order to identify and measure the protein of interest. It helps in identifying different types of proteins by their molecular weight. The most commonly used markers are bovine serum albumin, porcine serum albumin, human serum albumin, gelatin, and soybean trypsin inhibitor among others.
Nucleic Acid Marker:
Nucleic acid markers are molecules that are used for the detection of genetic material such as DNA or RNA in biological fluids. Nucleic acid markers have applications in clinical diagnostics, drug discovery & development, and forensic sciences. The most common types of nucleic acid markers include radioactive tracers, fluorescent dyes & colorants, and enzymes.
Application Insights:
Toxicological studies accounted for the largest share in 2015 and is anticipated to maintain its dominance over the forecast period. The rising prevalence of chronic diseases, growing environmental pollution load, and increasing focus on environment by various governments are some of the key factors driving this segment.
Metabolomics has been proved to be an effective tool for toxicology profiling which includes identification of biomarkers that reflect metabolic changes associated with toxicity. This technology helps identify a possible cause-and-effect relationship between a toxin and its effect on living cells by measuring cellular metabolism using mass spectroscopy techniques such as MALDI-TOF or LC/MS/MS. These technologies help detect low levels of toxins that may not necessarily show up in traditional assays such as ELISA or immunoassays due to limitations imposed by these methods (i.e., lack specificity).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of research entities, increased funding for metabolomics studies, and growing awareness among healthcare professionals regarding the utility of metabolomics biomarkers in disease management. Moreover, increasing adoption of advanced technologies such as mass spectrometry and high-throughput sequencing is further expected to drive regional growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising investments by pharmaceutical companies for developing novel drugs with improved efficacy and reduced side effects while maintaining stability at room temperature. In addition, an increase in chronic diseases prevalence rates coupled with growing demand for drug testing across various applications will support regional growth during the estimated time span (2018-2030).
Growth Factors:
- Increasing demand for personalized medicines
- Growing prevalence of chronic diseases
- Technological advancements in metabolomics biomarker research
- Rising public and private investments in metabolomics biomarker research
- Growing number of collaborations and partnerships between pharmaceutical companies, biotechnology companies, and academic institutions
Scope Of The Report
Report Attributes
Report Details
Report Title
Metabolomics Biomarker Market Research Report
By Type
Protein Marker, Nucleic Acid Marker
By Application
Toxicological studies, Drug testing, Cancer, Cardiovascular disorders, Neurological disorders, Inborn errors of metabolism
By Companies
Biocrates Life Sciences, Biomark Diagnostics, Chenomx, Creative Proteomics, Evotec, Human Metabolome Technologies, Merck, Metabolomic Diagnostics, Metabolon, Ovid Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
142
Number of Tables & Figures
100
Customization Available
Yes, the report can be customized as per your need.
Global Metabolomics Biomarker Market Report Segments:
The global Metabolomics Biomarker market is segmented on the basis of:
Types
Protein Marker, Nucleic Acid Marker
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Toxicological studies, Drug testing, Cancer, Cardiovascular disorders, Neurological disorders, Inborn errors of metabolism
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biocrates Life Sciences
- Biomark Diagnostics
- Chenomx
- Creative Proteomics
- Evotec
- Human Metabolome Technologies
- Merck
- Metabolomic Diagnostics
- Metabolon
- Ovid Therapeutics
Highlights of The Metabolomics Biomarker Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Protein Marker
- Nucleic Acid Marker
- By Application:
- Toxicological studies
- Drug testing
- Cancer
- Cardiovascular disorders
- Neurological disorders
- Inborn errors of metabolism
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metabolomics Biomarker Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metabolomics is the study of the chemical reactions that take place in cells and tissues. This information can be used to identify different diseases, assess drug effectiveness, and monitor patient health. Metabolomics biomarkers are specific molecules that are associated with disease or health conditions.
Some of the major companies in the metabolomics biomarker market are Biocrates Life Sciences, Biomark Diagnostics, Chenomx, Creative Proteomics, Evotec, Human Metabolome Technologies, Merck, Metabolomic Diagnostics, Metabolon, Ovid Therapeutics.
The metabolomics biomarker market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Metabolomics Biomarker Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Metabolomics Biomarker Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Metabolomics Biomarker Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Metabolomics Biomarker Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Metabolomics Biomarker Market Size & Forecast, 2020-2028
4.5.1 Metabolomics Biomarker Market Size and Y-o-Y Growth
4.5.2 Metabolomics Biomarker Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Protein Marker
5.2.2 Nucleic Acid Marker
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Toxicological studies
6.2.2 Drug testing
6.2.3 Cancer
6.2.4 Cardiovascular disorders
6.2.5 Neurological disorders
6.2.6 Inborn errors of metabolism
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Metabolomics Biomarker Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Metabolomics Biomarker Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Protein Marker
9.6.2 Nucleic Acid Marker
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Toxicological studies
9.10.2 Drug testing
9.10.3 Cancer
9.10.4 Cardiovascular disorders
9.10.5 Neurological disorders
9.10.6 Inborn errors of metabolism
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Protein Marker
10.6.2 Nucleic Acid Marker
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Toxicological studies
10.10.2 Drug testing
10.10.3 Cancer
10.10.4 Cardiovascular disorders
10.10.5 Neurological disorders
10.10.6 Inborn errors of metabolism
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Protein Marker
11.6.2 Nucleic Acid Marker
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Toxicological studies
11.10.2 Drug testing
11.10.3 Cancer
11.10.4 Cardiovascular disorders
11.10.5 Neurological disorders
11.10.6 Inborn errors of metabolism
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Protein Marker
12.6.2 Nucleic Acid Marker
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Toxicological studies
12.10.2 Drug testing
12.10.3 Cancer
12.10.4 Cardiovascular disorders
12.10.5 Neurological disorders
12.10.6 Inborn errors of metabolism
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Protein Marker
13.6.2 Nucleic Acid Marker
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Toxicological studies
13.10.2 Drug testing
13.10.3 Cancer
13.10.4 Cardiovascular disorders
13.10.5 Neurological disorders
13.10.6 Inborn errors of metabolism
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Metabolomics Biomarker Market: Competitive Dashboard
14.2 Global Metabolomics Biomarker Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biocrates Life Sciences
14.3.2 Biomark Diagnostics
14.3.3 Chenomx
14.3.4 Creative Proteomics
14.3.5 Evotec
14.3.6 Human Metabolome Technologies
14.3.7 Merck
14.3.8 Metabolomic Diagnostics
14.3.9 Metabolon
14.3.10 Ovid Therapeutics
